BMY vs. WAT: Bristol-Myers Squibb vs. Waters Stock Comparison

Company Profile

Bristol-Myers Squibb (BMY) and Waters (WAT) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BMY is classified in Pharmaceuticals while WAT is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Bristol-Myers Squibb (BMY) is heavily traded at around 10.85M shares per day, whereas Waters (WAT) sees a more moderate 816.72K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Bristol-Myers Squibb (BMY) at 44.01% sits in the top ROE quartile, while Waters (WAT) at 1.12% is closer to the peer norm — stronger capital efficiency for BMY.

Bristol-Myers Squibb (BMY) at 18.47% converts revenue to bottom-line profit above its industry’s benchmark range, while Waters (WAT) at 1.76% keeps roughly the typical share for its industry.

Bristol-Myers Squibb (BMY) at 33.79% operates in the top operating margin quartile, ahead of Waters (WAT) at 11.38%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Bristol-Myers Squibb (BMY) at -0.22% and Waters (WAT) at 6.99% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Waters (WAT) reports EPS growth of 0.47%, ranked against its industry; Bristol-Myers Squibb (BMY) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Short-term liquidity can only be read on one side of this pairing: Bristol-Myers Squibb (BMY) shows current ratio of 1.59 against its industry benchmark, while Waters (WAT) has no reading this period.

Waters (WAT) at 0.34 is near its industry mid-range for debt-to-equity ratio, while Bristol-Myers Squibb (BMY) at 1.91 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Waters (WAT) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bristol-Myers Squibb (BMY) reports a yield of 3.99%, ranking against industry peers normally.

Waters (WAT) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bristol-Myers Squibb (BMY) reports a payout of 55.88%, ranking against industry peers normally.

Dividend Metrics

Valuation

Bristol-Myers Squibb (BMY) at 13.78 is near its industry’s usual P/E ratio, while Waters (WAT) at 191.46 sits above its peer range — an unusually expensive price for WAT’s trailing earnings.

Bristol-Myers Squibb (BMY) at 2.54 sits in the cheaper P/S ratio quartile while Waters (WAT) at 8.01 prices around its industry’s middle — BMY costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Bristol-Myers Squibb (BMY) at 5.43 and Waters (WAT) at 2.94 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics